← Leaderboards
Lyndon L Key
Medical University Of South Carolina
$25,066
Attributed
$25,066
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$25,066 · 6
FDA$0 · 1
By mechanism
M01$25,066 · 6
R01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- L Judson Chandler$14,859,471
- Jacqueline F. McGinty$25,740,455
- Norman H Bell$1,281,695
- Patrick J Mulholland$10,153,446
- Michael David Scofield$3,304,026
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationImmunotherapyDiabetes Mellitus GeneticsSkeletal Disorder ChemotherapyChild (0-11)Bone MetabolismPhysiologic Bone ResorptionOutcomes ResearchPediatric PharmacologyInterferon GammaOsteopetrosisBiomarker1,25 DihydroxycholecalciferolBone MarrowCombination ChemotherapyAdolescence (12-20)Arab CountryChemopreventionGene MutationInsulin Dependent Diabetes MellitusFamily GeneticsHuman Puberty
Grant awards (17)
Phase II study of alendronate sodium in juvenile osteop*$0
R01 · FY2005 · FD
Phase II Study of Alendronate in Juvenile Osteoporosis$25,066
M01 · FY2004 · RR
CHARACTERISTICS &GENETICS OF ATYPICAL DIABETES MELLITUS$0
M01 · FY2002 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES$0
M01 · FY2002 · RR
INTERFERON GAMMA 1B IN TREATMENT OF OSTEOPETROSIS$0
M01 · FY2002 · RR
INTERFERON GAMMA 1B IN TREATMENT OF OSTEOPETROSIS$0
M01 · FY2001 · RR
CHARACTERISTICS &GENETICS OF ATYPICAL DIABETES MELLITUS$0
M01 · FY2001 · RR
CHARACTERISTICS &GENETICS OF ATYPICAL DIABETES MELLITUS$0
M01 · FY2001 · RR
CHARACTERISTICS &GENETICS OF ATYPICAL DIABETES MELLITUS$0
M01 · FY2001 · RR
INTERFERON GAMMA 1B IN TREATMENT OF OSTEOPETROSIS$0
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES$0
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES$0
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES$0
M01 · FY2001 · RR
INTERFERON GAMMA 1B IN TREATMENT OF OSTEOPETROSIS$0
M01 · FY2001 · RR
INTERFERON GAMMA THERAPY OF OSTEOPETROSIS$0
M01 · FY2000 · RR
THE HYPOPITUITARY CONTROL AND COMPLICATIONS STUDY$0
M01 · FY2000 · RR
INTERFERON GAMMA 1B IN TREATMENT OF OSTEOPETROSIS$0
M01 · FY2000 · RR